Am J Psychiatry 158:131-134, January 2001
© 2001 American Psychiatric Association
A Novel Augmentation Strategy for Treating Resistant Major Depression
Richard C. Shelton, M.D.,
Gary D. Tollefson, M.D., Ph.D.,
Mauricio Tohen, M.D., Dr.P.H.,
Stephen Stahl, M.D.,
Kimberley S. Gannon, Ph.D.,
Thomas G. Jacobs, M.S.,
William R. Buras, B.Sc.,
Frank P. Bymaster, M.Sc.,
Wei Zhang, M.D., Ph.D.,
Kimberley A. Spencer, B.Sc.,
Peter D. Feldman, Ph.D., and
Herbert Y. Meltzer, M.D.
OBJECTIVE: Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results. The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression. METHOD: An 8-week double-blind study was conducted with 28 patients who were diagnosed with recurrent, nonbipolar, treatment-resistant depression without psychotic features. Subjects were randomly assigned to one of three groups: olanzapine plus placebo, fluoxetine plus placebo, or olanzapine plus fluoxetine. RESULTS: Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression. The benefits of olanzapine monotherapy were modest. Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week. There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions. CONCLUSIONS: Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.
This article has been cited by other articles:
|
|
|
|
 
M. Valenstein, J. F. McCarthy, K. L. Austin, J. F. Greden, E. A. Young, and F. C. Blow
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
Am J Psychiatry,
July 1, 2006;
163(7):
1219 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. DeBattista
Augmentation and combination strategies for depression.
J Psychopharmacol,
May 1, 2006;
20(3 Suppl):
11 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. N Nguyen and S. K Guthrie
Risperidone Treatment of Bipolar Mania
Ann. Pharmacother.,
April 1, 2006;
40(4):
674 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Mann
The medical management of depression.
N. Engl. J. Med.,
October 27, 2005;
353(17):
1819 - 1834.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Fleck and E. Horwath
Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice
Psychiatr Serv,
August 1, 2005;
56(8):
1005 - 1011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Devarajan and S. M. Dursun
Olanzapine plus venlafaxine in treatment-resistant depression
J Psychopharmacol,
July 1, 2005;
19(4):
434 - 435.
[PDF]
|
|
|
|
|
|
|
G. Parker, H. Brotchie, and K. Parker
Is Combination Olanzapine and Antidepressant Medication Associated With a More Rapid Response Trajectory Than Antidepressant Alone?
Am J Psychiatry,
April 1, 2005;
162(4):
796 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Nierenberg, P. Eidelman, Y. Wu, and M. Joseph
Depression: An Update for the Clinician
Focus,
January 1, 2005;
3(1):
3 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Schatzberg
Recent Studies of the Biology and Treatment of Depression
Focus,
January 1, 2005;
3(1):
14 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Fochtmann and A. J. Gelenberg
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
Focus,
January 1, 2005;
3(1):
34 - 42.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Cowen
New drugs, old problems: REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION
Advan. Psychiatr. Treat.,
January 1, 2005;
11(1):
19 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. O. Cooper, G. B. Hickson, C. Fuchs, P. G. Arbogast, and W. A. Ray
New Users of Antipsychotic Medications Among Children Enrolled in TennCare
Arch Pediatr Adolesc Med,
August 1, 2004;
158(8):
753 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, T. S. Gray, D. N. D'Souza, G. A. Carrasco, K. J. Damjanoska, B. Dudas, F. Garcia, G. M. Zainelli, N. R. Sullivan Hanley, G. Battaglia, et al.
Desensitization of 5-HT1A Receptors by 5-HT2A Receptors in Neuroendocrine Neurons in Vivo
J. Pharmacol. Exp. Ther.,
July 1, 2004;
310(1):
59 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tohen, E. Vieta, J. Calabrese, T. A. Ketter, G. Sachs, C. Bowden, P. B. Mitchell, F. Centorrino, R. Risser, R. W. Baker, et al.
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Arch Gen Psychiatry,
November 1, 2003;
60(11):
1079 - 1088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Puig, P. Celada, L. Diaz-Mataix, and F. Artigas
In Vivo Modulation of the Activity of Pyramidal Neurons in the Rat Medial Prefrontal Cortex by 5-HT2A Receptors: Relationship to Thalamocortical Afferents
Cereb Cortex,
August 1, 2003;
13(8):
870 - 882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Stein, N. A. Kline, and J. L. Matloff
Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
October 1, 2002;
159(10):
1777 - 1779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. STIMPSON, N. AGRAWAL, and G. LEWIS
Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: Systematic review
The British Journal of Psychiatry,
October 1, 2002;
181(4):
284 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. BENAZZI
Fluoxetine and Olanzapine for Resistant Depression
Am J Psychiatry,
January 1, 2002;
159(1):
155 - 155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Shelton and A. J. Tomarken
Can Recovery From Depression Be Achieved?
Psychiatr Serv,
November 1, 2001;
52(11):
1469 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
